Source link : https://www.newshealth.biz/health-news/eu-oks-first-line-osimertinibchemo-for-egfr-advanced-nsclc/
The European Commission has approved Tagrisso (osimertinib; AstraZeneca) combined with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) harboring exon 19 deletions or L858R mutations. Lung cancer diagnoses in Europe exceed 450,000 annually.Approximately 10%-15% of patients with NSCLC in the […]
Author : News Health
Publish date : 2024-07-05 15:02:35
Copyright for syndicated content belongs to the linked Source.
Categories